Investing.com – Oppenheimer hat die Einstufung "Outperform" und das Kursziel von 205,00 US-Dollar für die Aktie von Biogen (NASDAQ: BIIB) nach der Veröffentlichung der Finanzergebnisse für das zweite ...

Discover key insights from Biogen's Q2 2025 earnings call: strong product launches, pipeline advancements, raised EPS guidance, and resilient MS ...

Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most ...

Biogen, one of the world's largest biotechnology companies, plans to invest $2 billion and build a new manufacturing facility ...

Investing.com - Truist Securities hat die Beobachtung der Biogen-Aktie (NASDAQ: BIIB) am Montag mit einer "Halten"-Einstufung und einem Kursziel von 142,00 $ aufgenommen. Laut Daten von InvestingPro w ...

Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has announced an update on its ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen, with a price target of $224.00. The company’s shares closed yesterday at $130.13. Do ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen, with a price target of $115.00. The company’s shares closed yesterday at $130.13. According to ...